Defunct Company
Total Trials
6
As Lead Sponsor
As Collaborator
0
Total Enrollment
388
NCT00126880
AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV
Phase: Phase 2
Role: Lead Sponsor
Start: Jul 31, 2005
Completion: Jan 31, 2008
NCT00334659
A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects
Phase: Phase 1
Start: Jun 30, 2006
Completion: Aug 31, 2006
NCT00352066
Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together
Start: Jul 31, 2006
NCT00367952
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
Start: Aug 31, 2006
Completion: Jan 31, 2010
NCT00612898
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
Phase: Phase 2/3
Start: Feb 29, 2008
NCT00686270
A Long Term Safety Study of Apricitabine in HIV-infected Patients
Phase: Phase 3
Start: May 31, 2008
Completion: May 31, 2012